Over 65s

Catch Them. You Can.

Over 65s

PNEUMOVAX® 23 (pneumococcal polysaccharide vaccine)
Prescribing Information [External link]

Prevent your patients over 65 from falling through the cracks. Help protect them against pneumococcal disease all year round with PPV23 - references 1,2
Elderly woman smiling into camera

PPV coverage rate in adults aged ≥65 up to March 20223

Approximately 28.5%

of adults ≥65 years old were unprotected against pneumococcal disease in 20223

Order and start vaccinating today

Check PPV23 stock status

PNEUMOVAX® 23 (PPV23) can be administered to all patients ≥65 years old at your clinic1,2 – all year round.

Ageing is associated with increased risk and severity of pneumococcal disease4

Over-65-year-olds have a higher risk of developing pneumococcal disease, longer duration of hospitalisation and/or higher rates of mortality.4–8

The increased risk may be due to:4

  • A weakened immune system (immunosenescence)
  • Presence of comorbidities/other health conditions 

Pneumonia is one of the leading causes of morbidity and mortality from infection in elderly patients9

Of the ~187,000 hospital admissions for community-acquired pneumonia (CAP) in 2019, >70% of patients were over 65 years of age10

You can help protect your patients from pneumococcal disease all year round*1 

Elderly man using nebuliser
Public health policy recommends PPV23 as part of the NHS National Immunisation Programme in the UK - reference 1

PNEUMOVAX® 23 offers immunisation against pneumococcal infections in all adults over 65 years*

You only need a single 0.5 mL dose (injected subcutaneously or intramuscularly) for most of your eligible patients.‡1,2 

Efficacy data

Based on real-world evidence:

For more information on the safety of PNEUMOVAX® 23, visit our Safety information page

PPV23 is in stock§ and available to order via ImmForm as part of the NHS National Immunisation Programme, and can be given to your COPD patients at any time during the year2,13,14 

Check PPV23 stock status

Find further resources on the use of PPV23 in your eligible patients on our Resources page

*PNEUMOVAX® 23 (pneumococcal polysaccharide vaccine) is recommended for active immunisation against pneumococcal disease in children aged from 2 years, adolescents and adults2
Revaccination may be needed in certain at-risk groups. The timing and need of revaccination should be determined on the basis of official recommendations and in line with the SmPC1,2 
A systematic review and meta-analyses of RCTs and observational studies investigating the efficacy of PPV23 against the specific outcomes PP and IPD in people aged ≥60 years living in industrialized countries. Overall, 4 clinical trials
(3 RCTs and one pseudo-randomized trial) and 13 observational studies were included12
§Subject to supply 

CAP = community acquired pneumonia; IPD = invasive pneumococcal disease; PCV = pneumococcal conjugate vaccine; PP = pneumococcal pneumonia; PPV = pneumococcal polysaccharide vaccine; RCT = randomised controlled trial; SmPC = summary of product characteristics; VE = vaccine efficacy


  1. The Green Book – Immunisation against infectious disease (January 2020). Chapter 25 – Pneumococcal. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/857267/GB_Chapter_25_pneumococcal_January_2020.pdf.
  2. Pneumovax-23 Summary of Product Characteristics.
  3. UK Health Security Agency. Pneumococcal Polysaccharide Vaccine (PPV) coverage report, England, April 2021 to March 2022. Available at: https://www.gov.uk/government/publications/pneumococcal-polysaccharide-vaccine-ppv-vaccine-coverage-estimates/pneumococcal-polysaccharide-vaccine-ppv-coverage-report-england-april-2021-to-march-2022.
  4. Grant LR, et al. Expert Rev Vaccines. 2021;20(6):691–705.
  5. Martins M, et al. BMJ Open Diabetes Res Care. 2016;4:e000181.
  6. Falcone M, et al. Medicine 2016;95(5):e2531.
  7. Restrepo MI, et al. Tuberc Respir Dis. 2018;81:187–197.
  8. Dai RX, et al. BMC Pulm Med. 2018;18(1):12.
  9. Chebib N, et al. Aging Clin Exp Res. 2021;33(4):1091–1100.
  10. Campling J, et al. J Med Econ. 2022;25(1):912–918.
  11. Streeter AJ, et al. PLoS One. 2022;17(10):e0275642.
  12. Falkenhorst G, et al. PLoS One. 2017;12(1): e0169368.
  13. UK Health Security Agency. The complete routine immunisation schedule from February 2022.
  14. National Institute for Health and Care Excellence. BNF Pneumococcal vaccine. Available at: https://bnf.nice.org.uk/treatment-summaries/pneumococcal-vaccine/.

By clicking the links above you will leave the MSD Connect website and be taken to third party websites

Supporting documentation

PNEUMOVAX® 23 (pneumococcal polysaccharide vaccine)
Prescribing Information

By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website